RNA vs SRPT

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Analysts rate Sarepta Therapeutics, Inc. (SRPT) a "Buy" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Atrium Therapeutics, Inc.

(RNA) delivered a total return of -51. 5%, compared to -81. 0% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: SRPT returned -16. 4% versus RNA's -55. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atrium Therapeutics, Inc.

(RNA) is the lower-risk stock at 1. 38β versus Sarepta Therapeutics, Inc. 's 2. 10β — meaning SRPT is approximately 52% more volatile than RNA relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Atrium Therapeutics, Inc. grew EPS -55. 0% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sarepta Therapeutics, Inc.

(SRPT) is the more profitable company, earning -32. 5% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps -32. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRPT leads at -29. 9% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RNA: 96.

1% to $25. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Atrium Therapeutics, Inc.

(RNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNA: -55. 3%, SRPT: -16. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.